Objective Network pharmacology was used to analyze the effective active components and mechanism of Gynostemma pentaphyllum in the treatment of osteoporosis. Methods The effective active components and targets of Gynostemma pentaphyllum through the Traditional Chinese Medicine Systems pharmacology Database and Analysis Platform （TCMSP）. Targets related to osteoporosis were identified by GeneCards，Therapeutic Target Database （TTD）,Online Mendelian Inheritance in Man （OMIM） and Pharmacogenomics Knowledgebase （PharmGKB） databases. The intersection of drug targets and disease targets was analyzed by protein-protein interaction network analysis，GO function enrichment analysis and KEGG pathway analysis. Results Twenty-four effective active components of Gynostemma pentaphyllum, including quercetin, rhamnazin and isofucosterol, were obtained, corresponding to 217 targets. Through the GeneCards, TTD, OMIM and PharmGKB database, 4620 osteoporosis related targets and 121 intersection targets were obtained.The protein-protein interaction network analysis showed that JUN proto-oncogene （JUN）, tumor protein P53 （TP53）, AKT serine/threonine kinase 1 （AKT1）, mitogen-activated protein kinase 1 （MAPK1）, RELA protooncogene （RELA）, estrogen receptor 1 （ESR1）, mitogen-activated protein kinase 14 （MAPK14）, Fos proto-oncogene(FOS), Myc proto-oncogene （MYC）, signal transducer and activator of transcription 1 （STAT1） may be the core targets of the herb in the treatment of the disease.GO functional enrichment analysis showed 1964, 43 and 160 entries in biological process, cell composition and molecular function, respectively. KEGG pathway enrichment analysis revealed 162 signaling pathways involving lipids, atherosclerosis, chemical carcinogene-receptor activation, etc. Conclusion This study initially revealed that Gynostemma pentaphyllum can treat osteoporosis through multiple components, multiple targets and multiple pathways, and its molecular mechanism may be related to JUN, TP53,AKT1, MAPK1, RELA, ESR1, MAPK14, FOS, MYC, STAT1 and other targets. These pathways involve lipids and atherosclerosis, chemical carcinogenic receptor activation, fluid shear stress and atherosclerosis, which lay a foundation for further research.
甄瑞峰;卢文君; 刘树娇. 基于网络药理学分析绞股蓝治疗骨质疏松症的机制研究[J]. 中国当代医药, 2022, 29(18): 11-17.
ZHEN Ruifeng ;LU Wenjun; LIU Shujiao. Mechanism research of Gynostemma pentaphyllum in treating osteoporosis based on network pharmacology. 中国当代医药, 2022, 29(18): 11-17.
Zhu HM，Qin L，Garnero P，et al．The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis[J]．Osteoporos Int，2012，23（4）：1317-1327.
Li F，Dong YZ，Zhang D，et al．Molecular mechanisms involved in drug－induced liver injury caused by uratelowering Chinese Herbs：A network pharmacology study and biology experiments[J]．PLoS One，2019，14（5）：e0216948．
AnterJ，Demyda-PeyrasS，DelPilarDelgadoM，etal.Biological and Health-promoting Activity of Vinification By-products Produced in Spanish Vineyards[J].S Afri J Enol Vitic，2015，36（1）：126-133.
Boots AW，Haenen GR，Bast A.Health effects of quercetin：From antioxidant to nutraceutical[J].Eur J Pharmacol，2008，585（2-3）：325-337.
[17]
Ahmed ZA，Abtar AN，Othman HH，et al．Effects of quercetin，sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats[J]．Drug Des Devel Ther，2019，13：3321－3329．
[18]
Cao H，Jia Q，Shen D，et al．Quercetin has a protective effect on atherosclerosis via enhancement of autophagy in Apo×10－/－mice[J]．Exp Ther Med，2019，18（4）：2451－2458．
[19]
Kim YJ，Bae YC，Suh KT，et al．Quercetin，a flavonoid，inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells[J]．Biochem Pharmacol，2006，72（10）：1268-1278．
[20]
Farr JN，Xu M，Weivoda MM，et al．Targeting cellular senescence prevents age-related bone loss in mice[J]．Nat Med，2017，23（9）：1072-1079．
[21]
Yuan Z，Min J，Zhao Y，et al．Quercetin rescued TNF-alphainduced impairments in bone marrow-derived mesenchymal stem cell osteogenesis and improved osteoporosis in rats[J]．Am J Transl Res，2018，10（12）：4313-4321．
[22]
Pang XG，Cong Y，Bao NR，et al．Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway[J]．BioMed Res Int，2018，2018：4178021.
[23]
Kawamura N，Kugimiya F，Oshima Y，et al.Akt1 in Osteoblasts and Osteoclasts Controls Bone Remodeling[J].PLoS One，2007，2（10）：e1058.
[24]
Mukherjee A，Rotwein P.Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development[J].Mol Cell Biol，2012，32（2）：490-500.
[26]
Lerbs T，Cui L，Muscat C，et al.Expansion of Bone Precursors through Jun as a Novel Treatment for Osteoporosis-Associated Fractures[J].Stem Cell Reports，2020，14（4）：603-613.
[28]
Mody N，Parhami F，Sarafian TA，et al.Oxidative stress modulates osteoblastic differentiation of vascular and bone cells[J].Free Radic Biol Med，2001，31（4）：509-519.
[29]
Byun CH，Koh JM，Kim DK，et al.Alpha-lipoic acid inhibits TNF-alpha-induced apoptosis in human bone marrow stromal cells[J].J Bone Miner Res，2005，20（7）：1125-1135.
[30]
Lee NK，Choi YG，Baik JY，et al.A crucial role for reactive oxyegn species in RANKL-induced osteoclast differentiation[J].Blood，2005，106（3）：852-859.
[31]
Park BG，Yoo CI，Kim HT，et al.Role of mitogen-activated protein kinases in hydrogen peroxide-induced cell death in osteobtastic cells[J].Toxicology，2005，215（1-2）：115-125.
[32]
陈雪．乏氧对脂多糖诱导的人牙周膜细胞炎症免疫反应的影响[D]．济南：山东大学，2019．
[33]
Hmamouchi I，Allali F，Khazzani H，et al.Low bone mineral density is related to atherosclerosis in postmenopausal Moroccan women[J].BMC Public Health，2009，9：388.
京公网安备 11010502046607号